J Clin Oncol: Women with breast cancer receiving anticancer therapy are associated with increased risk of cardiovascular disease and mortality

*Only for medical professionals to read and reference for 1 minute a day, to give you professional "talks" in the tumor circle! (For the original text, you can add Xiaobian WeChat yxj_oncology to get it) ▎Clinical question: Cardiovascular disease (CVD) and mortality in women with breast cancer (BC) who received anticancer therapy compared with women who did not receive breast cancer therapy Are there significant differences in risk? A prospective cohort study from J Clin Oncol examined whether there were significant differences in CVD and mortality risk among women with BC who received anticancer therapy compared with women who did not receive breast cancer therapy.
Screenshot of study publication▎Study protocol: The study matched 1:5 cases (n=13642) diagnosed with invasive BC from 2005 to 2013 with a control group without BC (n=68202) by year of birth and race/ethnicity , with a mean follow-up of 7 years (range <1-14 years)
.

Cancer treatment, CVD outcomes, and covariate data were obtained from electronic health records
.

Multivariable Cox proportional hazards models estimated hazard ratios (HRs) and 95% CIs for CVD morbidity and mortality after combined chemotherapy, radiotherapy, and endocrine therapy
.

▎Main findings: (1) Compared with the control group, women receiving anthracyclines and/or trastuzumab had a higher risk of heart failure/cardiomyopathy, and women receiving both anthracyclines and trastuzumab Resistant women had the highest risk of heart failure/cardiomyopathy (HR, 3.
68; 95% CI, 1.
79-7.
59)
.

(2) Compared with the control group, BC patients with a history of radiotherapy (HR, 1.
38; 95% CI, 1.
13-1.
69) and aromatase inhibitor use (HR, 1.
31; 95% CI, 1.
07-1.
60) also had There is a high risk of heart failure and/or cardiomyopathy
.

(3) The risk of stroke, arrhythmia, cardiac arrest, venous thromboembolic disease, CVD-related death, and death from any cause was also increased in BC patients treated for cancer
.

▎Deficiencies and Prospects: In conclusion, women with BC had increased rates of CVD events, CVD-related mortality, and all-cause mortality compared with women without BC, and the risk varied by cancer treatment history
.

Further research is needed to determine how women treated for BC should be cared for to improve cardiovascular outcomes
.

Reference materials: [1].
https://ascopubs.
org/doi/full/10.
1200/JCO.
21.
01736 The top journal essential assistant for clinical literature is online👇1.
Scan the QR code below the QR code to jump to "Top Journal Essence" To" H5 page 2.
Click "Download Now" 3.
Open the Doctor Station App and click on the column 4.
Find the "Top Issues Essentials" in the clinical medication, follow the column and subscribe to the column, and read a new top issue every day! Download the Doctor Station App and subscribe anytime, anywhere~